One of the most-watched Alzheimer's therapies in the clinic, Biogen Inc (NASDAQ:BIIB)-Eisai Limited's (OTC:ESALY) experimental lecanemab reduced clinical decline on the scale by 27% compared to the placebo at 18 months in early Alzheimer's. In July 2022, the FDA accepted the marketing application for lecanemab under the accelerated approval pathway and granted a Priority Review. The PDUFA date is Jan. 6, 2023. Also Read: This Analyst Believes Biogen's Lecanemab Data Not 'Slam Dunk' For Complete CMS Approval. Several stocks related to Alzheimer's programs are gaining. SVB Leerink said these positive results would reinvigorate the Alzheimer's...